Hemorrhagic manifestations in minority of patients
Therapeutic Considerations
Specific therapy evidence base
PALM randomized trial 2019 (NEJM)
mAb114 and REGN-EB3 superior to ZMapp and remdesivir
Low viral load survival rate 89-94% with mAb therapy
Trial stopped early due to clear benefit
WHO strongly recommends Inmazeb and Ebanga for all confirmed Zaire ebolavirus
Both agents have equivalent efficacy
Choice may depend on availability
Timing of therapy critical
Earlier initiation associated with better outcomes
Viral load at presentation strongest predictor of response
Supportive care principles
Aggressive electrolyte and fluid management backbone of care
ORS when tolerated; IV fluids when not
Nutritional support as core component
Empiric antimalarials reduce mortality through co-infection treatment
Avoid nephrotoxic drugs and NSAIDs
Vaccination strategy
rVSV-ZEBOV-GP (Ervebo)
Single-dose live vaccine
97.5% efficacy when given 10 or more days before exposure
Used in ring vaccination strategy in outbreak response
Vaccinated patients have 1.7x lower mortality if infected
Post-exposure prophylaxis
mAb114 or REGN-EB3 preferred for high-risk exposures
Immediate activity without 10-day gap of vaccine
rVSV-ZEBOV used as PEP within 48 hours in some settings
Infection control as therapeutic strategy
Early isolation reduces transmission and allows aggressive care
PPE compliance protects healthcare workforce
Contact tracing breaks transmission chain
Patient Discharge Instructions
copy discharge instructions
Post-Ebola recovery instructions
Complete all prescribed medications exactly as directed
Maintain adequate oral fluid intake
At least 2-3 litres of fluid daily
Electrolyte-containing drinks (sports drinks or ORS)
Rest and gradual return to activity
Fatigue may persist for months after discharge
Post-Ebola syndrome awareness
Most survivors experience at least one long-term symptom
Joint and muscle pain very common
Headache and fatigue may persist
Memory and concentration difficulties
Hearing loss possible
Eye and vision problems: uveitis can cause vision loss
Neuropsychiatric symptoms common
Depression and anxiety: seek mental health support
Cognitive changes may require evaluation
Important precautions
Male survivors: Ebola virus can persist in semen for 16 months or longer
Use condoms consistently until viral clearance confirmed by testing
Semen testing required before unprotected sex
Breast milk may contain Ebola virus
Avoid breastfeeding until cleared by medical team
Follow-up appointments required
Ophthalmology appointment for eye examination
Uveitis can develop and cause vision loss if untreated
Primary care physician within 1 week of discharge
Mental health services referral
Audiology if hearing changes noted
Rheumatology referral if joint problems develop
Return to emergency department immediately for
Recurrence of fever
Any bleeding from any site
Severe diarrhea or vomiting returning
Confusion or memory loss suddenly worsening
Eye pain or sudden vision change
Severe headache
Chest pain or difficulty breathing
Seizure
References
Guidelines and key sources
Primary clinical references
Chavez S, Koyfman A, Gottlieb M et al. Ebola Virus Disease: A Review for the Emergency Medicine Clinician. American Journal of Emergency Medicine. 2023
Comprehensive emergency medicine review
Symptom epidemiology and diagnostic approach
Malvy D, McElroy AK, de Clerck H et al. Ebola Virus Disease. Lancet. 2019
Comprehensive clinical review
Pathophysiology and clinical management
Feldmann H, Sprecher A, Geisbert TW. Ebola. New England Journal of Medicine. 2020
Virology and epidemiology review
Rojek A, Fieggen J, Apiyo P et al. Ebola Disease: Bridging Scientific Discoveries and Clinical Application. Lancet Infectious Diseases. 2025
Most recent comprehensive clinical review
Landmark therapeutic trials
Mulangu S, Dodd LE, Davey RT et al. PALM Trial. New England Journal of Medicine. 2019
Randomized controlled trial establishing mAb114 and REGN-EB3 superiority
Pivotal evidence base for current WHO recommendations
Gao Y, Zhao Y, Guyatt G et al. Network Meta-Analysis of EVD Therapies. Lancet Microbe. 2022
Systematic review confirming mAb superiority
Vaccine and prevention references
Kuehn R, Ryan H, Okwaraeke KC et al. Vaccines for Preventing Ebola Virus Disease. Cochrane Database of Systematic Reviews. 2024
rVSV-ZEBOV-GP efficacy data
Muyembe JJ, Pan H, Peto R et al. rVSV-ZEBOV-GP Ring Vaccination. New England Journal of Medicine. 2024
Ring vaccination strategy in DRC outbreak
Coulborn RM et al. Case Fatality Risk Among Vaccinated Individuals. Lancet Infectious Diseases. 2024
1.7x lower mortality in vaccinated patients
Long-term outcomes
Wohl DA, Fischer WA et al. Post-Ebola Symptoms 7 Years After Infection. Clinical Infectious Diseases. 2023
75% of survivors with symptoms at 1 year declining to 52% at 5 years
Ortega R, Bhadelia N et al. Putting On and Removing Personal Protective Equipment. New England Journal of Medicine. 2015
Video reference for PPE donning and doffing procedure
Cummings KJ, Choi MJ et al. Infection Prevention First US Community Hospital EVD Case. Annals of Internal Medicine. 2016
National recommendations for hospital preparedness
Rigby I, Michelen M et al. Standard of Care for Viral Haemorrhagic Fevers. Lancet Infectious Diseases. 2023
Systematic review of VHF clinical management guidelines
CDC Yellow Book: Post-Travel Evaluation to Rule Out Viral Special Pathogen Infection. 2025
Travel medicine and EVD risk evaluation guidance
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.